CB1 cannabinoid receptor antagonism for treating inflammation and arthritis

Expert Opinion on Therapeutic Patents

Volumn 17, Issue 8, 2007, Pages 1027-1031

  Lambert, Didier M ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Arthritis; Cannabinoid receptor; Carrageenan; CB1; Cytokines; Inflammation; TNF

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 [(2,4 DICHLOROPHENYL)AMINO] N [(TETRAHYDRO 2H PYRAN 4 YL)METHYL] 4 (TRIFLUOROMETHYL) 5 PYRIMIDINECARBOXAMIDE; 6 IODO 3 (4 METHOXYBENZOYL) 2 METHYL 1 (2 MORPHOLINOETHYL)INDOLE; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR ANTAGONIST; CANNABINOID RECEPTOR ANTAGONIST; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PROSTAGLANDIN E2; RIMONABANT; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTHRITIS; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CYTOKINE PRODUCTION; DRUG INDICATION; DRUG POTENCY; DRUG STRUCTURE; ENTERITIS; HUMAN; INFLAMMATION; NONHUMAN; PAIN; PATENT;

EID: 34548356939     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.17.8.1027     Document Type: Article

References (29)

1. HOWLETT AC, BREIVOGEL CS, CHILDERS SR, DEADWYLER SA, HAMPSON RE, PORRINO LJ: Carinabinoid physiology and pharmacology: 30 years of progress. Neuropharmacology (2004) 47(Suppl. 1):345-358.
2. LAMBERT DM, FOWLER CJ: The endocannabinoid system: drug targets, lead compounds, and potential therapeutic applications. J. Med. Chem. (2005) 48:5059-5087.
3. 1 cannabinoid receptor antagonists. Drug Discov. Today (2005) 10:693-702.
4. MUCCIOLI GG, LAMBERT DM: Current knowledge on the antagonists and inverse agonists of cannabinoid receptors. Curr. Med. Chem. (2005) 12:1361-1394.
5. MUCCIOLI GG, LAMBERT DM: latest advances in cannabinoid receptor antagonists and inverse agonists. Expert Opin. Ther. Patents (2006) 16:1405-1423.
6. MACKIE K: Distribution of cannabinoid receptors in the central and peripheral nervous system. Handb. Exp. Pharmacol. (2005) 299-325.
7. MACKIE K: Cannabinoid receptors as therapeutic targets. Ann. Rev. Pharmacol. Toxicol. (2006) 46:101-122.
8. HOWLETT AC, BARTH F, BONNER TI et al.: International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacologic. Rev. (2002) 54:161-202.
9. WILSON RI, NICOLL RA: Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature (2001) 410:588-592.
10. WILSON RI, NICOLL RA: Endocannabinoid signaling in the brain. Science (2002) 296:678-682.
11. HENNESS S, ROBINSON DM, LYSENG-WILLIAMSON KA: Rimonabant. Drugs (2006) 66:2109-2119.
12. BIFULCO M, GRIMALDI C, GAZZERRO P, PISANTI S, SANTORO A: Rimonabant: just an antiobesity drug? Current evidence on its pleiotropic effects. Mol. Pharmacol. (2007) 71:1445-1456.
13. PATEL PN, PATHAK R: Rimonabant: a novel selective cannabinoid-1 receptor antagonist for treatment of obesity. Am. J. Health Syst. Pharm. (2007) 64:481-489.
14. 1 antagonist on the control of metabolic hmctions in obese Type 2 diabetic patients. Diabetes Metab. (2007) 33:85-95.
15. 1 receptor antagonists as promising new medications for drug dependence. J. Pharmacol. Exp. Ther. (2005) 312:875-883.
16. VAN GAAL LF, RISSANEN AM, SCHEEN AJ, ZIEGLER O, ROSSNER S: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet (2005) 365:1389-1397.
17. SCHEEN AJ, FINER N, HOLLANDER P, JENSEN MD, VAN GAAL LF: Efficacy and tolerability of rimonabant in overweight or obese patients with Type 2 diabetes: a randomised controlled study. Lancet (2006) 368:1660-1672.
18. 1 cannabinoid receptor antagonism: a new strategy for the treatment of liver fibrosis. Nat. Med. (2006) 12:671-676.
19. RACHELEFSKY GS, OPELZ G, MICKEY MR et al.: Intact humoral and cell-mediated immunity in chronic marijuana smoking. J. Allergy Clin. Immunol. (1976) 58:483-490.
20. CROXFORD JL, YAMAMURA T: Cannabinoids and die immune system: potential for the treatment of inflammatory diseases? J. Neuroimmunol. (2005) 166:3-18.
21. VALENZANO KJ, TAFESSE L, LEE G et al.: Pharmacological and pharmacokinetic characterization of the cannabinoid receptor 2 agonist, GW405833, utilizing rodent models of acute and chronic pain, anxiety, ataxia and catalepsy. Neuropharmacology (2005) 48:658-672.
22. 2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br. J. Pharmacol. (2007) 150:153-163.
23. 2 receptors. Br. J. Pharmacol. (2007) 150:693-701.
24. ROMERO-SANDOVAL A, EISENACH JC: Spinal cannabinoid receptor type 2 activation reduces hypersensitivity and spinal cord glial activation after paw incision. Anesthesiology (2007) 106:787-794.
25. 2 receptor agonists. Curr. Med. Chem. (2007) 14:917-936.
26. 2 receptor agonist for the treatment of inflammatory pain. J. Med. Chem. (2007) 50:2597-2600.
27. 1 receptor antagonist rimonabant on nociceptive responses and adjuvant-induced arthritis in obese and lean rats. Br. J. Pharmacol. (2007) 150:559-566.
28. COSTA B: Rimonabant: more than an anti-obesity drug? Br. J. Pharmacol. (2007) 150:535-537.
29. PETROSINO S, PALAZZO E, DE N V et al.: Changes in spinal and supraspinal endocannabinoid levels in neuropathic rats. Neuropharmacology (2007) 52:415-422.